Research programme: toll-like receptor 3 monoclonal antibodies - Innate Pharma

Drug Profile

Research programme: toll-like receptor 3 monoclonal antibodies - Innate Pharma

Alternative Names: IPH 33; IPH-33-1; IPH-33-2

Latest Information Update: 19 Apr 2013

Price : $50

At a glance

  • Originator Innate Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Toll-like receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 12 Apr 2013 Initial pharmacodynamics data in Inflammation presented at the 104th Annual Meeting of the American Association for Cancer Research (AACR-2013)
  • 07 Mar 2013 Research programme: toll-like receptor 3 monoclonal antibodies - Innate Pharma is available for licensing as of 05 Mar 2013. www.innate-pharma.com
  • 05 Mar 2013 Preclinical trials in Inflammation in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top